When Voice-of-Customer Programs Strain Under Growth

Scaling voice-of-customer (VoC) programs in pharma’s clinical-research marketing is often messier than expected. Early-stage pilots thrive on personal relationships and manual follow-ups. But once you cross the threshold of dozens or hundreds of clinical sites, sponsors, and investigator networks, what worked in theory starts to break.

Teams expand, timelines shrink, and data floods in. Suddenly, you’re not just gathering insights—you’re managing volumes of input from principal investigators, site coordinators, regulatory affairs colleagues, and even patients enrolled in trials. Each voice carries nuances unique to drug development phases, therapeutic areas, or regional regulatory environments.

A 2023 PharmaVoice report observed that 62% of clinical marketing leaders struggle to maintain data quality and actionability beyond 25 active VoC touchpoints. It’s a common growth pain. The best manager marketers recognize that scaling VoC isn’t about doing more of the same; it’s about evolving the entire approach.

Framework for Scaling VoC: Structure Meets Discipline

If I had to distill the evolution of VoC programs across three pharma companies, here’s the framework that actually worked:

None of these are new concepts. What changes is the rigor and fidelity with which you apply them as complexity grows. Skimp on any, and the program bogs down in noise or bottlenecks.

Delegation: From Solo Hustle to Team Accountability

In smaller teams, the VoC lead often juggles everything—from designing surveys to presenting insights to senior stakeholders. This fast becomes unsustainable beyond 3-4 projects running in parallel.

What worked: creating specialized roles within a VoC pod. For example, assign one person to stakeholder relationship management (e.g., clinical operations, regulatory), another for data collection and cleaning, and a third for analysis and reporting.

One company I worked with moved from one VoC manager to a team of four in 18 months. By explicitly delegating ownership of each VoC channel (surveys, interviews, field reports), their project throughput doubled, and time-to-insight dropped from 6 weeks to 3.

The catch: delegation requires ironclad process documentation and regular check-ins. Without a clear RACI matrix and cadence meetings, tasks slip or get duplicated.

Standardized Processes: The Backbone of Consistency

Scaling VoC demands repeatable, predictable processes. That means no more ad hoc survey launches or “seat-of-the-pants” interview prepping.

A standardized feedback cycle might look like this:

• Monthly site coordinator pulse surveys via Zigpoll or Medallia
• Quarterly deep-dive interviews with key investigators
• Post-trial closeout focus groups
• Data aggregation and synthesis within two weeks after each cycle

Document every step—from question design to data storage location, to how anomalies get flagged. Standardization also means aligning on terminology, especially across global regions where “site satisfaction” or “protocol adherence” might be interpreted differently.

One pharma marketing lead shared that introducing feedback templates and playbooks reduced rework by 40%. When survey questions and interview guides became reusable assets, they could scale without sacrificing quality.

Technology: The Delicate Balance of Automation and Nuance

Pharma clinical research touches on highly regulated data and complex stakeholder networks. Your tech choices must respect compliance but also enable automation to handle scale.

Most teams start with standalone survey tools like Qualtrics or SurveyMonkey and a CRM like Salesforce. But these quickly become siloes.

The sweet spot found by several teams: a modular tech stack connected via APIs to automate repetitive tasks but still allow manual intervention for rich qualitative data.

For instance:

• Use Zigpoll for short, frequent site coordinator check-ins — quick to deploy, good for trend tracking
• Use Qualtrics for in-depth investigator surveys with branching logic and compliance controls
• Integrate survey data into a shared CRM or data warehouse for cross-functional visibility

Beware of over-automation. One clinical marketing team lost qualitative richness when they fully automated survey deployment without human follow-up. They saw a 20% drop in response rates and reduced context for closed-ended questions.

Measurement: Go Beyond Response Rates

VoC program metrics need to evolve as scale increases. Basic response rates and NPS scores won’t cut it alone.

Instead, track:

• Insight velocity: How quickly are you turning raw feedback into actionable reports?
• Cross-channel alignment: Are insights from surveys, interviews, and field reports telling the same story?
• Stakeholder engagement: What percentage of internal teams access and use the VoC data?
• Impact metrics: Changes in site retention, enrollment rates, or protocol compliance linked to VoC insights

For example, one company mapped VoC insights to site enrollment improvements. After acting on investigator feedback about protocol complexity, enrollment jumped from 45% to 63% for one Phase III trial arm.

Measurement requires upfront commitment. Without it, scaling VoC becomes a black box of data with no clear ROI.

Risks and Limitations: What Scaling Does Not Solve

Scaling VoC programs isn’t a silver bullet. Some challenges persist:

• Feedback fatigue: Even with automation, stakeholders like site coordinators can get overwhelmed by surveys. Rotating responder groups and spacing feedback cycles help, but there’s a natural limit.
• Over-standardization: Too rigid processes risk missing new or emerging issues that don’t fit established templates. Periodically revisit frameworks to stay relevant.
• Compliance hurdles: Especially in global trials, data privacy laws complicate feedback collection and sharing. Managers must work closely with legal teams early.

Also, scaling VoC is less useful if marketing leadership doesn’t prioritize acting on insights. A 2022 MM&M study found that 48% of pharma marketers say VoC data is underutilized because of organizational silos.

Scaling VoC: A Case in Point

At one mid-sized pharma company, the VoC team supported 150+ global clinical sites. They integrated quarterly Zigpoll check-ins for site leads with biannual qualitative interviews conducted by regional field reps.

Initially, the team manually processed all feedback. Six months in, they introduced workflow automation using Salesforce to tag issues, assign owners, and generate reports.

The result? Issue resolution time dropped from 28 days to 10 days. Enrollment delays tied to site feedback decreased by 30%.

But, the team also learned a lesson: automation couldn’t replace monthly “VoC huddles” where marketing, clinical ops, and regulatory reps reviewed issues live. That human element remained critical for scaling without losing nuance.

Scaling voice-of-customer programs in pharma clinical research marketing requires more than adding headcount or tools. It demands deliberate delegation, disciplined processes, a pragmatic tech mix, meaningful measurement, and an acceptance of inherent limitations.

Managers who treat VoC as a growing organism—not a static project—will build programs that deliver real insights and impact, even as complexity multiplies.